

Product Data Sheet

STAT3-IN-17

 $\begin{array}{lll} \textbf{Cat. No.:} & HY\text{-}148706 \\ \\ \textbf{CAS No.:} & 1245814\text{-}52\text{-}1 \\ \\ \textbf{Molecular Formula:} & \textbf{C}_{11}\textbf{H}_{6}\textbf{F}_{3}\textbf{N}_{3}\textbf{O}_{3}\textbf{S} \\ \end{array}$

Molecular Weight: 317.24

Target: STAT

Pathway: JAK/STAT Signaling; Stem Cell/Wnt

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

BIOLOGICAL ACTIVITY

Description	STAT3-IN-17 is a moderate STAT3 inhibitor (IC ₅₀ =0.7 μM; HEK-Blue IL-6), with antiproliferative activity in HeLa cells. STAT3-IN-17 has good pharmacokinetic characteristics. STAT3-IN-17 also inhibits pyruvate-ferredoxin oxidoreductase (PFOR), and inhibits Helicobacter pylori ^{[1][2]} .
IC ₅₀ & Target	STAT3
In Vitro	STAT3-IN-17 (compound 15) (10 μ M; 20 h, 48 h) inhibits STAT3 pathway with inhibition rate of 76.5%, and also inhibits HEK-Blue IL-6 cells viability to $15\%^{[1]}$. STAT3-IN-17 (2.5-40 μ M; 24 h) inhibits the phosphorylation of STAT3 (Y705) ^[1] . STAT3-IN-17 (10 μ M, 50 μ M; 48 h) inhibits HEK 293T cell growth, as well as inhibiting HeLa cell growth with an IC ₅₀ value of 2.7 μ M ^[1] . (D)-PPA 1 (compound 24) inhibits microorganisms Helicobacter pylori and Campylobacter jejuni with MIC values of 1.6 μ M and 4.7 μ M, respectively ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	STAT3-IN-17 (compound 15) (5 mg/kg for ig, or 25 mg/kg for iv; single dose) exhibits greater pharmacokinetic properties than Nitazoxanide (HY-B0217) in rat, with a significantly longer half-life for elimination (t1/2 β) (11.1 vs 0.8 h), greater absolute bioavailability (F) (87.4% vs 5.7%), and higher maximum plasma concentration (Cmax) (20.7 vs 1.0 mg/L) maximum plasma concentration (Cmax) (20.7 vs 1.0 mg/L) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

 $[1]. \ L\"{u}\ Z, et\ al.\ Structure-Activity\ Study\ of\ Nitazoxanide\ Derivatives\ as\ Novel\ STAT3\ Pathway\ Inhibitors.\ ACS\ Med\ Chem\ Lett.\ 2021\ Apr\ 1;12(5):696-703.$

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA